EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC 4.0

Long‐term trends in hepatitis C prevalence, treatment uptake and liver‐related events in the Swiss HIV Cohort Study

Lukas Baumann iD, Dominique L Braun, Matthias Cavassini iD, Marcel Stoeckle, Enos Bernasconi, Patrick Schmid, Alexandra Calmy, David Haerry, Charles Béguelin, Christoph A Fux, Gilles Wandeler iD, Bernard Surial iD und 1 weitere

Liver International · 2024

DOI: 10.1111/liv.15754 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Liver International, 2024. Verfasst von Lukas Baumann und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. Hauptthemen laut MEDLINE: Hepatitis C, Chronic, Drug Users, HIV Infections, Substance Abuse, Intravenous. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Treatment for chronic hepatitis C virus (HCV) infections changed dramatically in the last decade. We assessed changes in the prevalence of replicating HCV infection, treatment uptake and liver‐related morbidity and mortality in persons with HIV (PWH) and hepatitis C in the Swiss HIV cohort study.

Methods

We included all cohort participants between 2002 and 2021. We assessed yearly prevalence of replicating HCV infection, overall and liver‐related mortality, as well as the yearly incidence of liver‐related events in persons with at least one documented positive HCV‐RNA.

Results

Of 14 652 participants under follow‐up, 2294 had at least one positive HCV‐RNA measurement. Of those, 1316 (57%) ever received an HCV treatment. Treatment uptake increased from 8.1% in 2002 to a maximum of 32.6% in 2016. Overall, prevalence of replicating HCV infection declined from 16.5% in 2004 to 1.3% in 2021. HCV prevalence declined from 63.2% to 7.1% in persons who inject drugs, and from 4.1% to 0.6% in men who have sex with men. Among the 2294 persons with replicating HCV infection, overall mortality declined from a maximum of 3.3 per 100 patient‐years (PY) to 1.1 per 100 PY, and incidence of liver‐related events decreased from 1.4/100 PY to 0.2/100 PY.

Conclusions

The introduction of DAA therapy was associated with a more than 10‐fold reduction in prevalence of replicating HCV infection in PWH, approaching the estimates in the general population. Overall mortality and liver‐related events declined substantially in persons living with HIV and hepatitis C.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis C, ChronicDrug UsersHIV InfectionsSubstance Abuse, IntravenousSexual and Gender MinoritiesHepatitis CCoinfectionMaleHumansPrevalenceCohort StudiesHomosexuality, MaleAntiviral AgentsSwitzerlandHepacivirusRNA

Stichwörter der Autor:innen

DAAHCVHIVHIV coinfectionhepatitis Chepatitis C treatment outcomes

Substanzen

Antiviral AgentsRNA

Autor:innen und Institutionen

  • Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
  • Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
  • Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
  • Division of Infectious Diseases, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
  • Division of Infectious Diseases and Hospital Epidemiology, University of Basel, Basel, Switzerland.
  • Division of Infectious Diseases, Ente Ospedaliero Cantonale, Lugano, University of Geneva and University of Southern Switzerland, Lugano, Switzerland.

ORCID-Profile: Lukas Baumann, Matthias Cavassini, Gilles Wandeler, Bernard Surial

Förderung

  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung

Zitieren

APA

Baumann, L., Braun, D. L., Cavassini, M., Stoeckle, M., Bernasconi, E., Schmid, P., Calmy, A., Haerry, D., Béguelin, C., Fux, C. A., Wandeler, G., Surial, B., & Rauch, A. (2024). Long‐term trends in hepatitis C prevalence, treatment uptake and liver‐related events in the Swiss HIV Cohort Study. Liver International. https://doi.org/10.1111/liv.15754

Vancouver

Baumann L, Braun DL, Cavassini M, Stoeckle M, Bernasconi E, Schmid P, et al. Long‐term trends in hepatitis C prevalence, treatment uptake and liver‐related events in the Swiss HIV Cohort Study. Liver International. 2024. doi:10.1111/liv.15754

BibTeX
@article{Baumann2024,
  author = {Baumann, Lukas and Braun, Dominique L and Cavassini, Matthias and Stoeckle, Marcel and Bernasconi, Enos and Schmid, Patrick and Calmy, Alexandra and Haerry, David and Béguelin, Charles and Fux, Christoph A and Wandeler, Gilles and Surial, Bernard and Rauch, Andri},
  title = {Long‐term trends in hepatitis C prevalence, treatment uptake and liver‐related events in the Swiss HIV Cohort Study},
  journal = {Liver International},
  year = {2024},
  doi = {10.1111/liv.15754}
}
Kostenlos starten →